Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs

RecruitingOBSERVATIONAL
Enrollment

25,000

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions
Hepatitis C, Chronic
Interventions
DIAGNOSTIC_TEST

HCV RNA (PCR)

We will test HCV positive patients after treatment to observe if they achieve SVR

DIAGNOSTIC_TEST

HCV Antibody test (Point of care)

HCV antibody test used to establish if patients have had or are actively infected with HCV

DIAGNOSTIC_TEST

AST/ALT and platelets measurement

AST/ALT and platelets to determine APRI score

Trial Locations (1)

Unknown

RECRUITING

Aga Khan University, Karachi

All Listed Sponsors
collaborator

Aga Khan University

OTHER

collaborator

Dow University of Health Sciences

OTHER

collaborator

University of Oxford

OTHER

collaborator

University of Bristol

OTHER

lead

Queen Mary University of London

OTHER